Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: The STAR 3 experience

Diabetes Technology and Therapeutics

Volumn 13, Issue 6, 2011, Pages 601-606

  Buse, John B ^a   Dailey, George ^b   Ahmann, Andrew A ^c   Bergenstal, Richard M ^d   Green, Jennifer B ^e   Peoples, Tim ^f   Tanenberg, Robert J ^g   Yang, Qingqing ^f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SCRIPPS CLINIC   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d INTERNATIONAL DIABETES CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MEDTRONIC INC   (United States)

^g EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE;

ADULT; ARTICLE; CONTROLLED STUDY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MULTIPLE DAILY INJECTION THERAPY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SENSOR; SENSOR AUGMENTED PUMP THERAPY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MATERIALS TESTING; MIDDLE AGED; MODELS, BIOLOGICAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79957598950     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2010.0225     Document Type: Article

References (8)

1. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group: Effectiveness of sensor-augmented insulin pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-320.
2. Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV: STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Technol Ther 2010;12:249-255.
3. Green JB, Ahmann A, Bergenstal RM, Dailey G, Tanenberg R, Buse JB; STAR 3 Study Group: Glucose control in adults during a 1-year randomised controlled trial comparing sensor-augmented pump therapy and multiple daily injection therapy: STAR 3 study [abstract]. Diabetologia 2010;53(Suppl 1):S24.
4. Ahmann A, Buse JB, Bergenstal RM, Tanenberg R: HbA1c and sensor use in adults during a 1-year randomised controlled trial comparing sensor-augmented pump therapy and multiple daily injection therapy [abstract]. Diabetologia 2010;53(Suppl 1):S401.
5. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009;32:1947-1953.
6. Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, Zinman B: Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004;27:2590-2596. (Pubitemid 39441456)
7. Misso ML, Egberts KJ, Page M, OConnor D, Shaw J: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010;(1):CD005103.
8. Pickup JC, Sutton AJ: Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765-774.